Therapeutic potential of toll‐like receptors in treatment of gynecological cancers. Issue 5 (6th February 2019)

• Record Type: Journal Article
• Authors: Moradi‐Marjaneh, Reyhaneh; Hassanian, Seyed Mahdi; Hasanzadeh, Malihe; Rezayi, Majid; Maftouh, Mona; Mehramiz, Mehrane; Ferns, Gordon A.; Khazaei, Majid; Avan, Amir
• Is Part Of: IUBMB life. Volume 71:Issue 5(2019)
• Page Start: 549
• Page End: 564
• Publication Date: 2019-02-06
• Subjects: gynecological cancer -- toll‐like receptors -- anticancer agents; Biochemistry -- Periodicals; Molecular biology -- Periodicals; 572.8
• DOI: 10.1002/iub.2011
• Languages: English
• ISSNs: 1521-6543

Abstract

Abstract: Toll‐like receptors ( TLRs ) play an important role in the innate and adaptive immune system. They are expressed in various regions of the female reproductive tract, and their regulation may be involved in the pathogenesis of gynecological lesions. There is growing evidence that ligands for several TLRs are potentially anticancer agents, some of which have already been approved by the FDA, and these compounds are now undergoing clinical evaluation. There is a rationale for using these ligands as adjuvants in the treatment or prevention of gynecological cancer. Some TLR agonists that are of potential interest in the treatment of gynecological lesions include imiquimod, motolimod, cervarix, and CpG‐oligodeoxynucleotides (ODNs). In this review, we outline the different functions of TLRs in gynecological cancer with particular emphasis on the value of TLR agonists as a potential therapeutic target in the treatment of gynecological cancer. © 2019 IUBMB Life, 71(5):549–564, 2019